Le Tribunal de l'entreprise de Nivelles homologue le plan de restructuration de BioSenic
June 14, 2024 01:00 ET
|
BioSenic
COMMUNIQUÉ DE PRESSE – INFORMATION PRIVILEGIEE Mont-Saint-Guibert, Belgique, le 14 juin 2024, 7h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée...
The Enterprise Court of Nivelles approves the BioSenic restructuring plan
June 14, 2024 01:00 ET
|
BioSenic
PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious...
AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
June 13, 2024 18:22 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX
June 13, 2024 16:36 ET
|
Pomerantz LLP
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are...
Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
June 13, 2024 16:15 ET
|
Vaxart, Inc.
— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early...
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
June 13, 2024 16:05 ET
|
Ocular Therapeutix, Inc.
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 Announces plans for SOL-R study to evaluate repeat doses of...
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 13, 2024 16:01 ET
|
IN8bio, Inc
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO
June 13, 2024 14:38 ET
|
Pomerantz LLP
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) (NASDAQ: BBIO). Such investors are...
MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman
June 13, 2024 12:29 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Visit:...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALT
June 13, 2024 10:50 ET
|
Pomerantz LLP
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and certain...